Cefiderocol in context

Affiliations

Comment

Angela Huttner. Lancet Infect Dis. 2018 Dec.

. 2018 Dec;18(12):1290-1291.

doi: 10.1016/S1473-3099(18)30615-7. Epub 2018 Oct 25.

¹ Division of Infectious Diseases, Geneva University Hospitals, 1205 Geneva, Switzerland. Electronic address: Angela.huttner@hcuge.ch.

No abstract available

Comment on

Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
Portsmouth S, van Veenhuyzen D, Echols R, Machida M, Ferreira JCA, Ariyasu M, Tenke P, Nagata TD. Portsmouth S, et al. Lancet Infect Dis. 2018 Dec;18(12):1319-1328. doi: 10.1016/S1473-3099(18)30554-1. Epub 2018 Oct 25. Lancet Infect Dis. 2018. PMID: 30509675 Clinical Trial.